Phaseline

Targets › TFPI

TFPI (Tissue factor pathway inhibitor): drug programs, companies and trials

2 programs from 2 companies in 6 trials: 5 Phase 3, 1 Phase 1; Hematology; next expected readout Feb 2027.

Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma. (UniProt, P10646)

Open in Phaseline: the race on TFPI, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Novo NordiskConcizumab
Tissue factor pathway inhibitor inhibitor
TFPIPhase 3Haemophilia A With Inhibitors; Haemophilia A Without Inhibitors; Haemophilia A and B With and Without InhibitorsFeb 2027
Pfizermarstacimab
Tissue factor pathway inhibitor inhibitor
TFPIPhase 3Hemophilia A; Severe Hemophilia AMay 2027

Conditions

Hemophilia A (2) Severe Hemophilia A (1) Haemophilia A With Inhibitors (1) Haemophilia A Without Inhibitors (1) Haemophilia A and B With and Without Inhibitors (1)

Modalities

antibody (2)

Companies

Pfizer (1) Novo Nordisk (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.